From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
EBOV/MARV-IN-1 is a potent inhibitor of Ebola virus (EBOV) and Marburg virus (MARV), with broad-spectrum activity (EC50=0.31, and 0.82 µM, respectively) and low cytotoxicity (SI>100) in HeLa cells .
EBOV-IN-1 (com 3.47) is an adamantane dipeptide piperazine and an inhibitor of Ebola virus (EBOV). EBOV-IN-1 targets Niemann-Pick C1 (NPC1) and inhibits its binding to the EBOV glycoprotein (GP) that activates and mediates viral penetration into host cells, thereby inhibiting EBOV infection. EBOV-IN-1 inhibits pseudotyped EBOV infection with an IC50 of 13 nM .
EBOV-IN-4 (compound 12), a benzothiazepine, is a potent Ebola virus (EBOV) inhibitor with 64.9% inhibitory for EBOV-GP-pseudotype virus (pEBOV) with 10 μM. EBOV-IN-4 is inactive with ASFV .
EBOV-IN-5 (compound 14) is an antiviral agent that inhibits Ebola virus (EBOV) infection. EBOV-IN-5 inhibits the binding of the EBOV glycoprotein EBOV-GPcl to NPC1, an indispensable host receptor required for viral fusion/entry. .
EBOV-IN-7 (compound 26) is an inhibitor of the Ebola virus EBOV with an IC50 of 2.04 μM against EBOV-GP pseudotyped virus (pEBOV). EBOV-IN-7 has inhibitory effects on cancer cells and inhibits the EBOV-GPcl/NPC1 interaction. .
EBOV/MARV-IN-3 (compound 32) is a potent EBOV and MARV inhibitor with IC50 values of 0.5, 1.2 µM, respectively. EBOV/MARV-IN-3 binds to the hydrophobic pocket close to EBOV Y517. EBOV/MARV-IN-3 shows antiviral activity .
EBOV-IN-2 (Compound 2) is an inhibitor of Ebola virus (EBOV) with IC50 values of 0.37 μM and 2.54 against Ebola virus glycoprotein pseudotype virus (pEBOV) and African swine fever virus (ASFV), respectively .
CP19, a histamine receptor antagonist, is an entry inhibitor against both Ebolavirus (EBOV) and Marburgvirus (MARV) with IC50s of 3.4 μM and 29.5 μM, respectively. CP19 has SI values of 29.4 and 3.4 for EBOV and MARV, respectively. CP19 has antiviral activity .
Eritoran （E5564 free base） is a Toll-like receptor 4 (TLR4) antagonist. Eritoran protects mice against lethal influenza virus infection, such as Ebola virus (EBOV), Marburg virus (MARV). Eritoran decreases the level of granulocytosis, may alleviate the severity of the "cytokine storm". Eritoran inhibits pathogenesis of filovirus infection. Eritoran has anti-inflammatory activity .
Eritoran tetrasodium (E5564) is a Toll-like receptor 4 (TLR4) antagonist. Eritoran tetrasodium protects mice against lethal influenza virus infection, such as Ebola virus (EBOV), Marburg virus (MARV). Eritoran tetrasodium decreases the level of granulocytosis, may alleviate the severity of the "cytokine storm". Eritoran tetrasodium inhibits pathogenesis of filovirus infection. Eritoran tetrasodium has anti-inflammatory activity .
Toremifene-d6 (Z-Toremifene-d6) hydrochloride is deuterium labeled Toremifene. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively .
Anti-virus agent 1 (compound 4i), a phosphoramidate proagent of GS-5734 (HY-104077; Remdesivir), has potent antiviral activity. Anti-virus agent 1 is used for the research of coronavirus and Ebola virus (EBOV) .
IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy .
Cephaeline is a phenolic alkaloid in Indian Ipecac roots. Cephaeline exhibits potent inhibition of both Zika virus (ZIKV) and Ebola virus (EBOV) infections .
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection .
Cephaeline hydrochloride ((-)-Cephaeline hydrochloride) is a phenolic alkaloid in Indian Ipecac roots. Cephaeline hydrochloride exhibits potent inhibition of both Zika virus (ZIKV) and Ebola virus (EBOV) infections .
Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively .
Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively .
Retro-2 is a selective inhibitor of retrograde protein trafficking at the endosome-trans-Golgi network interface. Retro-2 is an ebolavirus (EBOV) infection inhibitor with an EC50 of 12.2 µM in HeLa cells. Retro-2 induces cell autophagy .
Toremifene-d6 is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].
Toremifene-d6 (citrate) is the deuterium labeled Toremifene citrate. Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].
Tilorone dihydrochloride is an orally active interferon (IFN) inducer with broad-spectrum antiviral activities. Tilorone dihydrochloride possesses robust anti-Severe fever with thrombocytopenia syndrome virus (SFTSV) activity in vitro and in vivo through stimulation of host innate immunity. Tilorone dihydrochloride can penetrate the blood-brain barrier to activate HIF in the CNS .Tilorone dihydrochloride exhibits an inhibitory activity with EC50 of 230 nM against Ebola virus (EBOV) .
R 59-022 (DKGI-I) is a DGK inhibitor (IC50: 2.8 µM). R 59-022 inhibits the phosphorylation of OAG to OAPA. R 59-022 is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils .
R 59-022 (DKGI-I) hydrochloride is a DGK inhibitor (IC50: 2.8 µM). R 59-022 hydrochloride inhibits the phosphorylation of OAG to OAPA. R 59-022 hydrochloride is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 hydrochloride potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils .
K777 is a potent, orally active and irreversible cysteine protease inhibitor. K777 is also a potent CYP3A4 inhibitor with an IC50 of 60 nM and a selective CCR4 antagonist featuring the potent chemotaxis inhibition. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 inhibits SARS-CoV and EBOV pseudovirus entry with IC50 values of 0.68 nM and 0.87 nM, respectively .
FGI-106 is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively .
FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively .
Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 µM and 1.8 µM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 µM and 1.8 µM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
Tamoxifen-d3 is the deuterium labeled Tamoxifen[1]. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[2][3][4]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[6]. Tamoxifen activates autophagy and induces apoptosis[5]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[7].
Tamoxifen (Standard) is the analytical standard of Tamoxifen. This product is intended for research and analytical applications. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
Tamoxifen-d3 hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection .
Cephaeline is a phenolic alkaloid in Indian Ipecac roots. Cephaeline exhibits potent inhibition of both Zika virus (ZIKV) and Ebola virus (EBOV) infections .
Cephaeline hydrochloride ((-)-Cephaeline hydrochloride) is a phenolic alkaloid in Indian Ipecac roots. Cephaeline hydrochloride exhibits potent inhibition of both Zika virus (ZIKV) and Ebola virus (EBOV) infections .
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein (AIE11917, HEK293, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein, expressed by HEK293 , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP Protein (AIE11917, HEK293, His) is 618 a.a., with molecular weight of ~69.3 kDa.
Ebola virus VP24 Protein is an IFN antagonist, and mediates nucleocapsid assembly. VP24 inhibits IFN-activated signaling by preventing nuclear import of STAT1 via competitive binding to nuclear import receptors (karyopherins). VP24 can interact with NP and is essential for nucleocapsid formation and packaging into the virion. Ebola virus VP24 Protein (AHX24653, His) is the recombinant Virus-derived Ebola virus VP24 protein, expressed by E. coli , with N-His labeled tag. The total length of Ebola virus VP24 Protein (AHX24653, His) is 233 a.a., with molecular weight of ~28.5 KDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein (Q05320, sf9, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP Protein (Q05320, sf9, His) is 618 a.a., with molecular weight of ~69.3 kDa.
Ebola virus glycoprotein (GP1), as a receptor-binding subunit, plays a key role in the virus entry process. During late stages of infection, GP1 downregulates key host cell surface molecules, including integrins such as ITGA1-6, disrupting adhesion and potentially leading to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein (Q7T9D9, HEK293, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein, expressed by HEK293 , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP Protein (Q7T9D9, HEK293, His) is 605 a.a., with molecular weight of ~67.9 kDa.
Ebola virus glycoprotein (GP1), as a receptor-binding subunit, plays a key role in the virus entry process. During late stages of infection, GP1 downregulates key host cell surface molecules, including integrins such as ITGA1-6, disrupting adhesion and potentially leading to disruption of vascular integrity. Ebola virus Glycoprotein/GP1 Protein (ACI28624, sf9, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP1 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP1 Protein (ACI28624, sf9, His) is 469 a.a., with molecular weight of ~53.5 kDa.
The Ebola virus NP/nucleoprotein is critical for viral genome protection and replication, forming a helical capsid to protect the genome. The VP35 interaction stabilizes the monomeric NP, maintaining solubility until replication triggers cooperative binding to viral RNA. Ebola virus NP/Nucleoprotein Protein (His) is the recombinant Virus-derived Ebola virus NP/Nucleoprotein protein, expressed by E. coli , with N-His labeled tag. The total length of Ebola virus NP/Nucleoprotein Protein (His) is 110 a.a., with molecular weight of ~15.6 kDa.
The Ebola virus NP/nucleoprotein is critical for viral genome protection and replication, forming a helical capsid to protect the genome. The VP35 interaction stabilizes the monomeric NP, maintaining solubility until replication triggers cooperative binding to viral RNA. Ebola virus NP/Nucleoprotein Protein (109a.a, Q5XX08, His) is the recombinant Virus-derived Ebola virus NP/Nucleoprotein protein, expressed by E. coli , with N-His labeled tag. The total length of Ebola virus NP/Nucleoprotein Protein (109a.a, Q5XX08, His) is 109 a.a., with molecular weight of ~14 kDa.
Ebola virus glycoprotein (GP1), as a receptor-binding subunit, plays a key role in the virus entry process. During late stages of infection, GP1 downregulates key host cell surface molecules, including integrins such as ITGA1-6, disrupting adhesion and potentially leading to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein RBD (ACI28624, HEK293, Fc) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein RBD, expressed by HEK293 , with C-hFc labeled tag. The total length of Ebola virus Glycoprotein/GP Protein RBD (ACI28624, HEK293, Fc) is 276 a.a., with molecular weight of ~57.6 KDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein RBD (Q05320, HEK293, Fc) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein RBD, expressed by HEK293 , with C-hFc labeled tag. The total length of Ebola virus Glycoprotein/GP Protein RBD (Q05320, HEK293, Fc) is 308 a.a., with molecular weight of ~57.6 KDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein RBD (Q05320, HEK293, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein RBD, expressed by HEK293 , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP Protein RBD (Q05320, HEK293, His) is 308 a.a., with molecular weight of ~32.3 KDa.
Ebola virus glycoprotein (GP1), as a receptor-binding subunit, plays a key role in the virus entry process. During late stages of infection, GP1 downregulates key host cell surface molecules, including integrins such as ITGA1-6, disrupting adhesion and potentially leading to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein (Q7T9D9, sf9, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP Protein (Q7T9D9, sf9, His) is 637 a.a., with molecular weight of ~67.9 kDa.
Ebola virus glycoprotein (GP1), as a receptor-binding subunit, plays a key role in the virus entry process. During late stages of infection, GP1 downregulates key host cell surface molecules, including integrins such as ITGA1-6, disrupting adhesion and potentially leading to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein RBD (Q7T9D9, HEK293, Fc) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein RBD, expressed by HEK293 , with C-hFc labeled tag. The total length of Ebola virus Glycoprotein/GP Protein RBD (Q7T9D9, HEK293, Fc) is 320 a.a., with molecular weight of ~59 KDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein (AHX24649, sf9, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP Protein (AHX24649, sf9, His) is 618 a.a., with molecular weight of ~69.3 kDa.
Ebola virus VP40 (matrix VP40 protein) centrally directs virus assembly and budding and has complex interactions with viral ribonucleocapsid and host ESCRT proteins (VPS4, PDCD6IP/ALIX, NEDD4, TGS101). Ebola virus VP40/Matrix VP40 Protein (YP_138522, His-MBP) is the recombinant Virus-derived Ebola virus VP40/Matrix VP40 protein, expressed by E. coli , with N-His, N-MBP labeled tag. The total length of Ebola virus VP40/Matrix VP40 Protein (YP_138522, His-MBP) is 326 a.a., with molecular weight of ~79.1 kDa.
Ebola virus VP40 (matrix VP40 protein) centrally directs virus assembly and budding and has complex interactions with viral ribonucleocapsid and host ESCRT proteins (VPS4, PDCD6IP/ALIX, NEDD4, TGS101). Ebola virus VP40/Matrix VP40 Protein (Q5XX06, His) is the recombinant Virus-derived Ebola virus VP40/Matrix VP40 protein, expressed by E. coli , with N-His labeled tag. The total length of Ebola virus VP40/Matrix VP40 Protein (Q5XX06, His) is 296 a.a., with molecular weight of ~34.5 kDa.
The Ebola virus NP/nucleoprotein is critical for viral genome protection and replication, forming a helical capsid to protect the genome. The VP35 interaction stabilizes the monomeric NP, maintaining solubility until replication triggers cooperative binding to viral RNA. Ebola virus NP/Nucleoprotein Protein (378a.a, Q5XX08, His) is the recombinant Virus-derived Ebola virus NP/Nucleoprotein protein, expressed by E. coli , with N-His labeled tag. The total length of Ebola virus NP/Nucleoprotein Protein (378a.a, Q5XX08, His) is 378 a.a., with molecular weight of ~44.1 kDa.
Ebola virus VP40/Matrix VP40 Protein is essential for assembling and budding virus particles, interacting with host proteins linked to the multivesicular body pathway. Ebola virus VP40/Matrix VP40 Protein (B8XCM9, His) is the recombinant Virus-derived Ebola virus VP40/Matrix VP40 protein, expressed by E. coli , with N-His labeled tag. The total length of Ebola virus VP40/Matrix VP40 Protein (B8XCM9, His) is 296 a.a., with molecular weight of ~34.4 kDa.
Ebola virus glycoprotein (GP1), as a receptor-binding subunit, plays a key role in the virus entry process. During late stages of infection, GP1 downregulates key host cell surface molecules, including integrins such as ITGA1-6, disrupting adhesion and potentially leading to disruption of vascular integrity. Ebola virus Glycoprotein/GP1 Protein (501a.a, Q7T9D9, sf9, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP1 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP1 Protein (501a.a, Q7T9D9, sf9, His) is 501 a.a., with molecular weight of ~52.5 kDa.
Ebola virus glycoprotein (GP1), as a receptor-binding subunit, plays a key role in the virus entry process. During late stages of infection, GP1 downregulates key host cell surface molecules, including integrins such as ITGA1-6, disrupting adhesion and potentially leading to disruption of vascular integrity. Ebola virus Glycoprotein/GP1 Protein (501a.a, Q7T9D9, HEK293, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP1 protein, expressed by HEK293 , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP1 Protein (501a.a, Q7T9D9, HEK293, His) is 501 a.a., with molecular weight of ~52.5 kDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP1 Protein (AHX24649, HEK293, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP1 protein, expressed by HEK293 , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP1 Protein (AHX24649, HEK293, His) is 501 a.a., with molecular weight of ~52.3 kDa.
Ebola virus glycoprotein (GP1), as a receptor-binding subunit, plays a key role in the virus entry process. During late stages of infection, GP1 downregulates key host cell surface molecules, including integrins such as ITGA1-6, disrupting adhesion and potentially leading to disruption of vascular integrity. Ebola virus Glycoprotein/GP1 Protein (Q7T9D9, sf9, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP1 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP1 Protein (Q7T9D9, sf9, His) is 320 a.a., with molecular weight of ~33.8 KDa.
Ebola virus glycoprotein (GP1), as a receptor-binding subunit, plays a key role in the virus entry process. During late stages of infection, GP1 downregulates key host cell surface molecules, including integrins such as ITGA1-6, disrupting adhesion and potentially leading to disruption of vascular integrity. Ebola virus Glycoprotein/GP1 Protein (Q7T9D9, HEK293, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP1 protein, expressed by HEK293 , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP1 Protein (Q7T9D9, HEK293, His) is 320 a.a., with molecular weight of 46-64 kDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP1 Protein (AHX24649, sf9, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP1 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP1 Protein (AHX24649, sf9, His) is 469 a.a., with molecular weight of ~52.3 KDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein RBD (AHX24649, HEK293, Fc) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein RBD, expressed by HEK293 , with C-hFc labeled tag. The total length of Ebola virus Glycoprotein/GP Protein RBD (AHX24649, HEK293, Fc) is 308 a.a., with molecular weight of ~57.6 KDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein RBD (AHX24649, HEK293, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein RBD, expressed by HEK293 , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP Protein RBD (AHX24649, HEK293, His) is 308 a.a., with molecular weight of ~32.3 KDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP2 Protein (AHX24649, HEK293, Fc) is the recombinant Virus-derived Ebola virus Glycoprotein/GP2 protein, expressed by HEK293 , with N-mFc labeled tag. The total length of Ebola virus Glycoprotein/GP2 Protein (AHX24649, HEK293, Fc) is 149 a.a., with molecular weight of ~43.4 KDa.
Ebola virus VP40 (matrix VP40 protein) centrally directs virus assembly and budding and has complex interactions with viral ribonucleocapsid and host ESCRT proteins (VPS4, PDCD6IP/ALIX, NEDD4, TGS101). Ebola virus VP40/Matrix VP40 Protein (AHX24648, His) is the recombinant Virus-derived Ebola virus VP40/Matrix VP40 protein, expressed by E. coli , with N-6*His labeled tag. The total length of Ebola virus VP40/Matrix VP40 Protein (AHX24648, His) is 296 a.a., with molecular weight of ~34.1 KDa.
Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP Protein (AHX24649, HEK293, His) is the recombinant Virus-derived Ebola virus Glycoprotein/GP protein, expressed by HEK293 , with C-His labeled tag. The total length of Ebola virus Glycoprotein/GP Protein (AHX24649, HEK293, His) is 650 a.a., with molecular weight of ~54.8 kDa.
Ebola virus VP40 (matrix VP40 protein) centrally directs virus assembly and budding and has complex interactions with viral ribonucleocapsid and host ESCRT proteins (VPS4, PDCD6IP/ALIX, NEDD4, TGS101). Ebola virus VP40/Matrix VP40 Protein (AHX24648, His-MBP) is the recombinant Virus-derived Ebola virus VP40/Matrix VP40 protein, expressed by E. coli , with N-His, N-MBP labeled tag. The total length of Ebola virus VP40/Matrix VP40 Protein (AHX24648, His-MBP) is 326 a.a., with molecular weight of ~78.7 kDa.
Toremifene-d6 (Z-Toremifene-d6) hydrochloride is deuterium labeled Toremifene. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively .
Toremifene-d6 is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].
Toremifene-d6 (citrate) is the deuterium labeled Toremifene citrate. Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].
Tamoxifen-d3 is the deuterium labeled Tamoxifen[1]. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[2][3][4]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[6]. Tamoxifen activates autophagy and induces apoptosis[5]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[7].
Tamoxifen-d3 hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
Inquiry Online
Your information is safe with us. * Required Fields.
